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BACKGROUND 
What are the special nutritional needs of prem-
ature or growth-impaired infants? 
 Advancements in medical care within the 
past two decades have led to increased survival 
rates of premature infants.1 Nutrition interven-
tions are an important aspect of care for these 
vulnerable infants and need to be continually re-
evaluated as new research and clinical findings 
are available. However, meeting the nutritional 
needs of premature infants is challenging because 
of their limited nutrient reserves, need for rapid 
growth, decreased absorption of nutrients, imma-
ture organs, and increased risk for infection. Due 
to their low birth weight, it is known that infants 
born prematurely do not have sufficient protein 
and micronutrient stores because the majority of 
fetal nutrient accretion occurs during the third 
trimester of pregnancy. 2,3 In general, premature 
(<37 weeks of gestation), low birth weight (LBW 
<2500g), and very low birth weight (VLBW, <1500 
g) infants have higher needs of calories, protein, 
minerals (calcium, phosphorus, sodium, zinc, 
iron), and Vitamin D compared to term infants.4,5,6  
Nutrient needs of extremely premature (<30 
weeks gestation) are even greater. Fortification of 
breast milk is a practice used to reach these in-
creased nutrient needs while providing many of 
the benefits of human milk. 
 Very preterm infants, who are typically 
too developmentally immature to suckle until ap-
proximately 34 weeks gestational age, are provid-
ed nutrition initially via parenteral nutrition (PN). 
Enteral feedings with expressed breast milk is 
initiated as soon as medically appropriate.1 Paren-
teral nutrition is tapered with the goal to discon-
tinue PN as soon as full enteral feeds of expressed 
breast milk are reached in order to decrease risk 
of infection through the central line access.7 Thus 
the premature infant’s immunocompromised sta-
tus has nutritional implications and necessary 
sanitary measures should be implemented to re-
duce risk of infections. 
 However, enteral nutrition for premature 
infants face unique challenges. Premature infants 
have an immature gastrointestinal (GI) tract, 
which leads to decreased motility and increased 
gut permeability. This makes providing adequate 
nutrition difficult because the premature infant’s 
GI tract has malabsorption of nutrients, increased 
risk of feeding intolerance, and increased risk of 
infection, especially after extended periods of no 
enteral intake. Feeding intolerance is a term used 
to summarize clinical symptoms of reflux, emesis, 
large gastric residual volumes, abdominal disten-
tion causing a decrease, delay, or discontinuation 
of feeds and/or visible abdominal loops on 
am.8,11 In addition, the premature infant’s imma-
ture GI tract and increased gut permeability in-
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crease the infant’s risk of developing inflammation 
and severe tissue damage associated with ne-
crotizing enterocolitis (NEC) once enteral feeds 
are initiated.9 NEC is a particularly high-risk ad-
verse health outcome due to its high case-fatality 
ratio, high likelihood of requiring a surgical pro-
cedure and complications such as GI stricture, 
short-bowel syndrome, and cholestasis.5,10 Feed-
ing intolerance and NEC are frequently the cause 
of delayed advancement of enteral feedings in 
premature infants.7,11,12,41 Delayed provision of full 
nutritional support and onset of these adverse 
clinical outcomes result in cumulative energy and 
protein deficits that in turn negatively impact 
postnatal growth outcomes.7 
 Premature-LBW infants are born with 
decreased bone mineral density thus are already 
at increased risk for osteopenia of prematurity, 
fractures, and rickets. LBW infants have increased 
needs for calcium, phosphorus, zinc, and Vitamin 
D to promote bone mineralization.13 In addition, 
the risk of osteopenia, rickets, and collapsed ver-
tebrae is elevated among LBW infants who require 
parenteral nutrition as sole source of nutrition for 
extended periods of time because parenteral nu-
trition regimens cannot provide adequate calcium 
and phosphorus due to osmolality and solubility 
limitations.14 Once enteral feeds become the pri-
mary source of nutrition, it remains important to 
monitor adequacy of mineral and micronutrient 
intake to prevent osteopenia of prematurity and 
anemia.  
 The best source of nutrition will meet the 
increased nutrient needs of premature infants, 
support growth, and limit micronutrient and mac-
ronutrient deficiencies while simultaneously de-
creasing risk for adverse health outcomes. See 
Table 1 for a description of select nutrient needs 
that have changed in recent years for LBW infants, 
which are similar to those born prematurely who 
do not meet LBW criteria. 
 To meet their special needs while provid-
ing breast milk, the American Academy of Pediat-
rics recommends fortifying breast milk for:15  
 Infants younger than 34 weeks gestation 
 Infants weighing less than 1500g at birth 
 LBW infants who require greater than 2 
week of parenteral nutrition, as PN does 
not provide adequate micronutrients 
 LBW infants with suboptimal growth or 
high acuity nutritional risks caused by 
medical conditions or complications of 
prematurity 
Breast milk fortification is appropriate for these 
infants because they are born without adequate 
nutrient stores and have higher nutrient needs 
than breast milk can provide. Despite these rec-
ommendations, however, there is still substantial 
controversy about the most appropriate use of 
human milk fortifiers (HMF). There is still concern 
that in the attempt to meet premature infants’ 
nutrient needs for growth human milk fortifiers 
may actually counteract the immunoprotective 
benefits of breast milk by increasing the risk for 
other adverse clinical outcomes. This review 
summarizes the strategies of human milk fortifica-
tion that have developed in recent years to pro-
mote growth in premature-low birth weight in-
fants while minimizing adverse health events, 
such as necrotizing enterocolitis (NEC), feeding 
intolerance, late onset sepsis (LOS), osteopenia, 
metabolic acidosis, and anemia. 
 To evaluate the extent to which current 
evidence supports these strategies, this review 
aims to: (i) highlight the health outcomes that 
need be considered to identify optimal feeding 
regimens for these vulnerable infants; (ii) de-
scribe the evidence supporting the use of fortified 
human milk rather than enhanced infant formula; 
and (iii) review the evidence on benefits and risks 
related to the form, content, and administration of 
these fortifiers, which provides the scientific basis 
for current practice. There are, for example, de-
bates related to the micronutrient and macronu-
trient content, use of liquid vs. powdered formula-
tions to obtain ideal osmolality and to reduce risk 
of infection, and individualization of both dose 
and duration of these fortifiers. These factors and 
others appear to have an important impact on 
numerous health outcomes in these vulnerable 
infants.  
Nutrient VLBW (>1000g)  
Tsang, 2005 
VLBW (>1000g)  
ESGPHAN, 2010 
Fluid 135-190mL/kg 135-200mL/kg 
Energy 110-130 kcal/kg 110-135 kcal/kg 
Carbohydrate 7-17 g/kg 11.6-13.2g/kg 
Protein 3.4-4.2g/kg 3.5-4.0g/kg 
Protein:Energy --- 3.2-3.6g /100kcal 
Fat 5.3-7.2 g/kg 4.8-6.6 g/kg 
Minerals   
Calcium 100-220 mg/kg 120-140mg/kg 
Phosphorus 60-140 mg/kg 60-90 mg/kg 
Magnesium 7.9-15mg/kg 8-15 mg/kg 
Sodium 69-115 mg/kg 
(3-5mEq/kg) 
69-115mg/kg 
Potassium 78-117mg/kg 
(2-3 mEq/kg) 
66-132 mg/kg 
Chloride 107-249 mEq/kg 105-177 mg/kg 
Trace Elements   
Zinc 1000-3000 mcg/kg 1.1-2.0 mg/kg 
Copper 120-150mcg/kg 10-132 mg/kg 
Iron 2-4 mg/kg 2-3 mg/kg 
Vitamins   
Vitamin D 150-400 IU/kg 800-1000 IU/d 
Vitamin B12 0.3 mcg/kg 0.1-0.77mcg/kg 
Folic acid 25-50 mcg/kg 35-100mcg/kg 
Table 1. Nutrient Needs for Intrauterine 
Grwoth 
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1. DEFINING OPTIMAL GROWTH AND 
DEVELOPMENT TARGETS 
How can we assess whether infant feeding reg-
imens are optimal for growth and health? 
Defining the best source of nutrition that can meet 
these increased nutrient needs of premature-LBW 
infants has been difficult partly due to the conflict-
ing data regarding the optimal growth rate for 
premature infants. It was once thought that opti-
mal growth was synonymous with the growth rate 
that mimics the rapid body mass accretion that 
occurs during the third trimester. Growth charts 
for premature infants, such as the Fenton, are 
based on these intrauterine growth rate projec-
tions.16,17,18 Preterm formula was heralded as the 
growth success story because it often helped 
premature infants achieve much more rapid 
growth rates than breast milk.19,20However, more 
recent data has shown that rapid catch-up growth 
in small for gestational age infants is a risk factor 
for adult onset cardiovascular disease,21,22 adult 
onset leptin resistance and obesity5 and insulin 
resistance as a teenager.18 While these observa-
tional studies were not focused on premature in-
fants, the research findings from these studies 
does beg the question as to whether current crite-
ria for evaluating optimal feeding regimens, based 
on rapidly achieving intrauterine growth, are ideal 
given uncertainty about long-term health out-
comes.23 Even though some studies have associat-
ed early postnatal suboptimal weight gain with 
later low cognitive function, others have found 
that breastfed infants have improved neurodevel-
opment in spite of insufficient weight gain, a phe-
nomenon termed the “apparent breastfeeding 
paradox”. 23 Despite the limited and conflicting 
data, in the absence of clear alternatives, the gen-
eral consensus still remains that achieving intrau-
terine growth rates of 15-20g/kg/d are both pos-
sible and ideal for premature infants with birth 
weights between 1000g and 1800g to achieve as 
their extra-uterine growth rate.13,17,18,20 
 Growth outcomes alone are not sufficient 
to assess the optimal nutrition source for prema-
ture and low birth weight infants.  Nutrition goals 
should also seek to reduce the premature infant’s 
risk for adverse nutrition-related clinical out-
comes including necrotizing enterocolitis (NEC), 
osteopenia of prematurity, metabolic acidosis, 
jaundice, anemia, late onset sepsis and other infec-
tions, prolonged feeding intolerance, compro-
mised gut integrity, and death compared to term 
infants and infants >1500g.  
  
2. NUTRITIONAL AND IMMUNE DEFICIENCIES 
OF THE PRETERM AND/OR GROWTH-
IMPAIRED INFANT 
What is the rationale for fortifying human milk 
vs. providing enhanced preterm formula? 
 Breast milk is considered the best source 
of nutrition for all newborns15 due to the high bio-
availability of nutrients in breast milk and the 
immunoprotective benefits it bestows on the in-
fant. For premature infants, specifically, consump-
tion of human milk is associated with a more rapid 
achievement of full feeds, improved feeding toler-
ance, reduction in incidence of NEC & sepsis, 
shorter hospital stay, fewer hospital readmissions 
up to 30 months after discharge, and improved 
brain development and neurodevelopmental out-
come when compared to a diet of preterm formu-
la.4,5,24,25 Overall these improved health outcomes 
from breastfeeding result in reduction of 
healthcare costs for premature newborns.4 In-
deed, breast milk is associated with better health 
outcomes than formula with the exception of 
growth outcomes defined using current crite-
ria.6,14,15,19,24,25 
 The variability of nutrient content and 
inadequate levels of some nutrients in breast milk 
have associated it with poorer growth outcomes 
compared to infant formulas. In contrast, preterm 
formulas have the advantage of consistently deliv-
ering nutrients at pre-determined levels that can 
be easily manipulated. Preterm infant formulas 
have been re-formulated in recent years to con-
tain adequate levels of minerals but they lack the 
growth hormones and immunological properties 
of breast milk.26 Human milk fortifiers (HMF) are 
added to breast milk in order to maximize the de-
livery of micro- and macronutrients as an addition 
to the other beneficial components of breast milk. 
In addition, human milk fortification is not associ-
ated with an increased risk of NEC unlike preterm 
formulas.24 However, despite the inability to sup-
port intrauterine growth rates, a meta-analysis 
founds no differences in feeding tolerance when 
comparing premature infants fed fortified human 
milk or unfortified human milk.19 Despite the im-
provements in preterm formulas, fortifying hu-
man milk is considered ideal for these at-risk in-
fants.  
 
What are nutrient deficiencies in premature 
maternal milk?  
 Despite initially high nutrient density, 
concerns remain about the adequacy of the breast 
milk mothers of premature infants for achieving 
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current criteria for optimal growth and develop-
ment. At first premature milk is higher in fat and 
protein compared to term breast milk, which 
helps meet the high caloric demands of a prema-
ture infant.6 The exact content of energy and pro-
tein in breast milk, however, will vary throughout 
the day, within each expression, over the course of 
lactation, and from mother to mother.27 This re-
duces the certainty of nutrient intake and can re-
sult in deficiencies in the premature infant. In ad-
dition, premature milk does not contain adequate 
levels of calcium, phosphorus, Vitamin D, and iron 
to meet the needs of the premature infant.5 Exclu-
sively breastfed preterm and LBW infants who do 
not receive adequate levels of calcium, phospho-
rus, and Vitamin D are at increased risk for osteo-
penia of prematurity.27 Two weeks after birth, 
breast milk from the mother of a premature infant 
will decline in content of fat, protein, sodium, and 
zinc to levels found in breast milk from the mother 
of a term infant.27 The protein content of prema-
ture breast milk will continue to progressively 
decline in the first 4-6 weeks.4 However, the nu-
trient needs for preterm infant remain elevated 
during this time of nutrient decline.27,28 Unforti-
fied preterm human milk are unable to provide 
the general caloric requirements of 110-
135kcal/kg/d and minimum protein intake of 
3.4g/kg/d to support the optimal average weight 
gain of 15 to 20 g/day in preterm, LBW infants.3,5 
Consequently, American Academy of Pediatrics 
(AAP), US Food and Drug Administration (FDA), 
American Academy of Nutrition and Dietetics 
(AND), World Health Organization (WHO), Euro-
pean Society of Paediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN), American 
Society for Parenteral and Enteral Nutrition 
(ASPEN), American Board of Physician Nutrition 
Specialists (ABPNS) currently recommend fortify-
ing preterm milk.    
 
What are the nutrient deficiencies in donor 
milk?  
 In instances where a mother’s own breast 
milk is unavailable donor, human milk is the best 
substitute but has increased nutrient deficien-
cies.15 Donor milk is often from mothers express-
ing milk for term infants, which is lower in protein 
and fat content compared to preterm milk.4 The 
donor milk is combined with several donors and 
pasteurized creating batches of donor milk with 
levels of minerals, protein, and fat that can vary 
across samples. The Holder pasteurization process 
for donor milk heats milk at 62.5°C for 30 minutes, 
which decreases the “activity of many of the func-
tional bioactive factors in milk.”27  The increased 
handling and storage of donor milk decreases ca-
loric content as fat adheres to the walls of each 
container.4 Protein content of donor breast milk 
diminishes through the pasteurization and chang-
ing temperatures during storage.27 Thus, there 
are greater concerns related to the adequacy of 
donor milk than preterm milk.  
 Despite these concerns, however, a study 
by Colaizy et al., (2012)29 found that there were 
“no statistically significant differences in the prev-
alence of neonatal morbidities that may influence 
growth”—including NEC and sepsis—between 
extremely premature-VLBW infants who received 
majority of their intake as donor milk and those 
who received majority of their intake as maternal 
milk. More studies are needed to determine 
whether the decrease in bioactive components in 
donor breast milk decreases the immunoprotec-
tive and neurological development benefits found 
with mother’s own breast milk for preterm in-
fants.  
 Due to its limited availability in clinical 
practice, donor breast milk is preferentially pro-
vided to premature infants and infants with mal-
absorption, allergy, short gut, and chronic lung 
disease, which are conditions prevalent among 
premature infants.30 These disease states further 
increase the infant’s nutrient demands. Given the 
larger nutrient deficits of both calories and pro-
tein, donor breast milk would require greater nu-
trient fortification to meet the growth require-
ments for premature infants. It is not surprising 
that in trials studying the growth & health out-
comes associated with different milk types the 
extremely premature-VLBW infants receiving 
predominantly pasteurized donor human milk 
required more nutritional supplements yet per-
sisted with a slower rate of weight gain27 and had 
higher rates of small-for-gestational-age (SGA) at 
discharge3 than infants receiving formula or ma-
ternal milk. These findings indicate that donor 
breast milk may require a different fortification 
strategy than mother’s own breast milk in order to 
support growth in preterm infants. Nevertheless, 
UNICEF and WHO “have issued a joint resolution 
support the use of banked donor milk as the ‘first 
alternative’ for infants whose mothers are unable 
tobreastfeed.”30 
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3. OPTIMIZING THE NUTRIENT CONTENT 
DELIVERED BY HUMAN MILK FORTIFIERS 
How is human milk fortified? 
 Commercial human milk fortifiers (HMF) 
are designed as multi-nutrient supplements to 
provide adequate macronutrients and micronutri-
ents without exceeding safe limits of osmolality. 
Until recently, commercial HMF were powders 
added to expressed breast milk but recent HMF 
products have been developed in liquid form. 
 Standard HMF mixing protocols increase 
the caloric content of breast milk from 20 kcal to 
22kcal/oz or 24kcal/oz. HMF contain differing 
quantities of minerals but are intended to meet 
the increased needs of premature-LBW infant in 
order to promote adequate bone mineralization 
and prevent anemia. 
 Due to the high levels of micronutrients, 
additional fortification with HMF in order to in-
crease caloric or protein intake would result in 
excessive intake of minerals. One particular case 
study also found that high levels of calcium fortifi-
cation could lead to calcium fatty acid insoluble 
soaps in the infant’s gut thus inhibiting absorption 
and obstructing the bowel31 and leading to lower 
weight gain.40 There was also concern that that 
these multi-nutrient fortifiers would counteract 
the anti-bacterial properties in breast milk. It was 
found that the high iron content of formulas facili-
tate the growth of gram-negative bacteria associ-
ated with NEC.32 Translating this to HMF, the con-
cern was that multi-nutrient fortifiers containing 
iron would reduce the breast milk’s innate inhibi-
tion of gram-negative bacteria. However, a recent 
study revealed that higher levels of iron within the 
multi-nutrient fortifier or addition of iron with 
multi-nutrient fortifiers does not affect bacterial 
growth in human milk.33   
 Preterm infant formulas or modular sup-
plements are used to increase the caloric content 
up to 27 kcal/oz or 30kcal/oz if needed. The calor-
ic density of the feeding will depend on the in-
fant’s growth velocity, needs due to any medical 
complications, and fluid restrictions or volume 
tolerance. Individual modular supplements for 
protein, carbohydrates, multivitamins, and miner-
als are needed when the commercial human milk 
fortifiers cannot meet the nutritional needs of the 
infant.34 However, adding all of these nutrients as 
individual modular supplements to breast milk 
increases the chance of dose error and potential 
for contamination. Nutrients individually or col-
lectively added in too high of a dose can result in 
an osmolality of breast milk above the recom-
mended upper limit of 450mosm/kg.35 Hyperos-
molar feeds increase the risk for NEC14 and more 
likely to result in diarrhea.19 The use of modular 
supplements in neonatal intensive care units var-
ies across the country likely due to lack of evi-
dence on efficacy and safety to guide best practic-
es. 
 
Are human milk fortifiers providing sufficient 
protein? 
  A central focus of current debate on HMF 
is on whether multi-nutrient fortifiers supply op-
timal protein energy content (g/kg/d) and a suffi-
cient protein to energy ratio (grams protein per 
100kcal) in order to optimize growth for prema-
ture infants. Optimal protein feeding for prema-
ture infants has been defined based on fetal nutri-
tion. In utero, protein is the main energy source 
for fetal body mass accretion. Protein has been 
identified as a growth-limiting factor for preterm 
infants as these infants have a much higher need 
for protein compared to term infants, in order to 
achieve current criteria for optimal growth.36,16  
However, breast milk provides a greater propor-
tion of calories from lipids and glucose and lower 
amounts of protein than the fetus would receive in 
utero, creating concern about optimal postnatal 
protein nutrition.2 If total energy intake is limited 
then the available protein is used for energy pro-
duction and lean body mass accretion is hindered. 
As overall calorie intake increases, protein is 
spared and nitrogen retention increases thus im-
proving lean body mass accretion. If sufficient en-
ergy is provided yet protein intake is limited then 
nitrogen retention plateaus and the excess energy 
is used for fat deposition.37,2 Total daily energy 
intake, total daily protein intake, and the proper 
ratio of grams of protein per 100kcals is im-
portant for supporting growth in the preterm in-
fant. 
 Assessments of the protein adequacy of 
HMFs is further complicated as recent studies 
have found that multi-nutrient fortification of 
breast milk according to manufacturers labels did 
not provide adequate protein content. Due largely 
to the variability in breast milk protein content, 
the actual protein content of the fortified preterm 
breast milk was frequently lower than recom-
mended intake of protein38 and protein: energy 
ratio.39  Reports vary on the assumed protein con-
centration of human milk ranging from 
1.2g/100ml 40  to 1.4 to 1.6 g/100ml46 to 
1.9g/100ml.18 These protein levels are likely de-
rived from reports on protein content during dif-
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ferent stages of lactation: 2-3g/100ml in colos-
trum, 1.3-7.8g/100ml in transitional milk, and 1.3-
1.8g/100ml in later milk.20 This variation resulted 
in a wide range of protein concentration offered in 
various brands of powder HMF (between 0.7 and 
1.1g protein/100ml).46 These protein concentra-
tions did not account for the decrease in protein in 
breast milk over time thus yielding a protein en-
ergy ratio and total protein intake insufficient for 
VLBW/ELBW infants to achieve fetal weight gain 
rates.40  
 Indeed, use of HMF has been associated 
with high rates of extra-uterine or postnatal 
growth failure, defined as growth <10th percentile 
on intrauterine growth projection at a given gesta-
tional age, among ELBW. Several studies have 
shown that very few VLBW infants—as few as 2% 
of VLBW infants born 30-35 weeks41—are able to 
achieve intrauterine growth rates even while re-
ceiving fortified human milk.42,7 The National In-
stitute of Child and Human Development (NICHD) 
Neonatal Research Network reported that “16% of 
extremely low birth weight infants are small for 
gestational age at birth, but by 36 weeks corrected 
age, 89% have growth failure.”43 Since majority 
(84%) of the birth weights of these ELBW infants 
are born appropriate for gestational age (i.e. their 
weights are ~50th percentile weight-for-
gestational age) then their low birth weight is at-
tributable to being born prematurely and is not 
indicative of intrauterine growth failure. However, 
after birth the growth failure indicates the infants 
are not receiving adequate nutrition in order to 
achieve intrauterine growth rates. Such growth 
failure is a concern because it has been associated 
with poor psychomotor development at 18 
months44 and neurodevelopmental impairment at 
18mo and 22mo corrected gestational age.11,43,45 
 
Table 232: Calorie recommendations for Low Birth-
weight Infants 
Professional Medical Organi-
zation 
Recommenda-
tions 
European Society for Pediatric 
Gastroenterology, Hepatology, 
and Nutrition (ESPGAN), 1991 
98-128kcal/kg/d 
Canadian Paediatric Society 
(CPS) Nutrition Committee, 
1995 
105-135 
kcal/kg/d 
American Academy of Pediatrics 
(AAP) Committee on Nutrition, 
1998 
105-130 
kcal/kg/d 
Life Sciences Research Office 
(LSRO), 2002 
110-135 
kcal/kg/d 
ESPGAN, 2010 110-135 
kcal/kg/d 
 Studies implementing more aggressive protein 
concentrations in EBM fortification for extreme-
ly premature, VLBW infants: 
 In response to these findings, recommen-
dations for calorie and protein intake for prema-
ture, VLBW infants have increased over the years. 
These recommendations suggest more aggressive 
nutrition protocols that aim to supply protein and 
calories earlier and in higher concentrations (Ta-
ble 2 and Table 3). Though limited, several studies 
do not suggest strategies to improve growth out-
comes with increased protein concentrations in 
fortifiers provided to VLBW infants, based on ex-
isting growth criteria. For example, two studies, 
Miller et al. (2012)46 and Kanmaz et al. 2012)48, 
compared growth outcomes among preterm-LBW 
infants fed expressed breast milk (EBM) randomly 
assigned to treatment groups of varying levels of 
protein fortification. Both studies enrolled infants 
with a median gestational age at birth < 30 weeks 
and median birth weight <1200g. Given these de-
mographics, these infants require 3.5-4.0g pro-
tein/kg/d and 3.2g protein:100kcal according to 
ESPGHAN recommendations.37  
 Given two studies with infants of similar 
birth weights, gestational age, and protein sup-
plementation, the growth outcomes in terms of 
weight gain rate did not improve with greater pro-
tein intake. Neither of the studies demonstrated 
significantly different weight gain rate or length 
increments across their respective fortification 
groups (Kanmaz etal. 3.6 v 3.3 v 3.0 g pro-
tein/kg/d and Miller etal. 4.2 v 3.6g protein/kg/d) 
(i.e. greater protein intake did not result in rela-
tive increases in weight gain rates). Yet all of the 
preterm, VLBW infants enrolled in the Kanmaz et 
al. (2012) study achieved intrauterine growth 
rates (15-20gm/kg/d) regardless of their protein 
intake. Even the infants receiving 3.0g/kg/d, 
which is below the recommended protein intake 
for infants between 1000g and 1800g, achieved 
intrauterine growth rates.  
 In terms of other growth outcome 
measures, Kanmaz et al. (2012) saw a significantly 
greater weekly increase in head circumference in 
those infants receiving 3.3 g protein/kg/d and 3.6 
g protein/kg/d compared to those infants receiv-
ing 3.0 g protein/kg/d. The improvements in head 
circumference growth are important because this 
anthropometric measure has the strongest link to 
long-term improvement of neurocognitive devel-
opment.45  Where Kanmaz et al. (2012) saw im-
provements in growth outcomes (achieving intra-
uterine growth weight gain and head circumfer-
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ence increase) among infants receiving 3.6g pro-
tein/kg/d compared to 3.0g protein/kg/d,  
Miller et al. (2012) did 
not find improvements in growth outcomes (inci-
dence of weight SGA, rate of length or head cir-
cumference) among infants receiving 4.2g pro-
tein/kg/d compared to 3.6g protein/kg/d.46  
 The differing growth outcomes highlight 
the difficulty of defining protein recommendations 
for premature, VLBW infants. There was signifi-
cantly less extra-uterine growth failure in terms of 
length, but not for weight, among infants receiving 
4.2 g protein/kg/d compared to 3.6g protein/k/d. 
Infants receiving 3.6g/kg/d achieved greater gains 
in head circumference increase rate, but not 
weight gain rate, than those infants who received 
a standard human milk fortifier containing 
3.0gram/kg/d. Ultimately, these findings support 
the ESPGHAN recommendations because an in-
crease of protein intake within the recommended 
range did achieve intrauterine growth rates and 
improvements in head circumference increments. 
Exceeding the recommended range of protein in-
take did not  result in adverse clinical outcomes 
nor did it necessarily improve growth outcomes. 
  Some of the differences seen in weight 
gain rates and increases in head circumferences 
could be attributed to the differing methods of 
enteral and parenteral nutrition protocols for all 
of the infants. For example, Kanmaz initiated hu-
man milk fortification for all the infants once en 
teral feeding volume reached 90-100ml/kg 
whereas Miller initiated fortification at a median 
volume rate of 120ml/kg. In addition, Kanmaz 
specified that the parenteral nutrition protocol 
was started at a dose of 2.3g amino acids/kg/d 
immediately after delivery and reached 4g/kg/d 
on day 3 of life. These more aggressive nutrition 
protocols could have minimized the differences 
seen between the various human milk fortification 
groups in the Kanmaz study and facilitated meet-
ing intrauterine growth rates even with lower 
protein intakes. The variations seen in these stud-
ies highlight the differences seen in clinical prac-
tice when defining enteral nutrition initiation 
practices, “full feeding” volumes, and balance be 
tween parenteral and enteral nutrition admin-
istration.7,26,41  
 In addition, it is important to note that 
these studies used preterm formula when human 
milk when breast milk was not available. This may 
have confounded the results but it is a reality of 
clinical practice that preterm breast milk or donor 
milk is not always available in sufficient supply 
thus making the results more generalizable to 
general clinical practice. In fact, a survey of US 
NICUs found that “breastmilk was administered as 
the first feeding the majority of the time (75.4%), 
Table 3: Protein and Protein: Energy Ratios recommendations 
  Weight <1000g Weight >1000g 
 g pro-
tein/kg/d 
g protein/100kcal g protein/kg/d g protein/100kcal 
ESPGHAN, 198747 -- 2.25-3.1  2.25-3.1 
Kashyap & Heird, 199420,3 - - 3.0 2.5 
LSRO, 200220 3.4-4.3 2.5-3.6 3.4-4.3 2.5-3.6 
Tsang, 200514 3.8-4.4 2.5-3.6 3.4-3.6 2.8 
ESPGHAN, 201037 4.0-4.5 3.6-4.1 3.5-4.0 3.2-3.6 
Ziegler, 20113 4.0 3.7 3.6 2.8 
 
Table 4: Growth Outcomes with varying levels of protein fortification 
 Kanmaz et al, 2012* Miller et al, 2012 
3.0g protein 
/kg/d 
3.3g protein 
/kg/d 
3.6g protein 
/kg/d 
3.6g protein 
/kg/d 
4.2g protein 
/kg/d 
Daily weight gain (g/d) 19.7 + 4.43a 20.6 + 5 21.4 + 4.7 26 (24-28) c 24 (20-28) 
Weekly increase in head 
circumference, (cm) 
0.69 + 0.21 b 0.92 + 0.22 b 0.82 + 0.21b  0.95  
(0.92-0.99) 
0.94  
(0.9-0.98) 
Length at dis-
charge/study end (cm)d 
41.7 + 2.33 42.05 + 2.17 41.7 + 2.32 45.5 + 3.0 46.3 + 2.1 
*achieved 16.4 + 2.2g/kg/d in 3.0g protein/kg/d,  17.1 + 3.4 g/kg/d in 3.3g protein/kg/d, 17.8 + 3.2g/kg/d in 3.6g pro-
tein/kg/d, (P=0.38).  
a Mean + SD (all such values) 
b P2= .001; only p-value <.05 
c Median; 25th-75th percentile in parentheses (all such values) 
d From enrollment to study end; study end occurred when the infant was discharged from hospital or reached expected date 
of delivery, whichever occurred first 
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with almost all (89.6%) of respondents reporting 
the administration of infant formula “some of the 
time” at the time of first feeding”.1 Even though 
evidence suggests premature infants should be 
provided breastmilk exclusively, the reality is that 
premature infants are receiving different sources 
of nutrition. Nutrition care teams need to priori-
tize supporting mothers of premature infants to 
provide breastmilk as early as possible and as 
much as possible to their child. 
 
Other clinical outcomes with higher protein in-
takes 
 These studies often exclude infants for 
feeding intolerance, development of NEC or other 
GI-related complications. For instance, one patient 
in Miller et al. (2012) study dropped out of the 
study due to perceived feeding intolerance yet 
there was no statistically significant differences in 
the incidence of clinical outcomes including NEC, 
sepsis, length of stay, time to reach full enteral 
feeds, days feeding was interrupted, or number of 
days receiving TPN between the fortification 
groups (4.2g protein/kg/d v 3.6g protein/kg/d). 
Similarly, the extra protein supplied in Kanmaz et 
al. (2012) study (3.6 v 3.3 v 3.0g protein/kg/d) 
was not associated with detrimental health out-
comes, such as metabolic acidosis, NEC, feeding 
intolerance, or serum indicators for osteopenia.48 
Incidence of feeding tolerance and NEC was simi-
lar across all groups of protein fortification in both 
the Miller et al and Kanmaz et al study, which in-
dicates feeding tolerance was still an issue. Other 
studies have found that exceeding 4g pro-
tein/100ml of breast milk does not provide any 
nutritional advantage in terms of growth and can 
result in uraemia or hyperaminoacidemia, which 
is associated with developmental delays.35 This 
raises the idea that perhaps it is the concentration 
of protein rather than total intake of protein per 
day that could be related to adverse clinical out-
comes. Other evidence suggests that better man-
agement of enteral feeds can reduce feeding intol-
erance and other adverse health outcomes such as 
NEC. For example, the use of trophic feeds, early 
small enteral volumes, has been beneficial in 
maintaining intestinal integrity.13 Slow rate ad-
vancement to reach goal enteral feeding rate can 
also reduce the incidence of these adverse health 
outcomes.9  
 
Are there benefits to individualizing breast milk 
fortification for preterm infants? 
 The concern for extra-uterine growth re-
striction despite fortification and no reduction in 
adverse clinical outcomes when intrauterine 
growth rates are achieved has pushed the idea of 
individualizing additional fortification of breast 
milk.  As the Miller & Kanmaz studies show, addi-
tional protein intake allow some infants to achieve 
intrauterine growth rates while extra-utrine 
growth failure persists in others. Researchers be-
lieve that individualization of intake will meet the 
infant’s nutrient needs based on the wide variety 
of conditions and needs of premature infants.  
 Nutrition recommendations and NICU 
protocols have been individualized by weight of 
the infant rather than gestational age/degree of 
prematurity because weight is seen as a better 
indicator of the possible nutrient deficits among 
premature infants. Recommendations from Euro-
pean Society for Paediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHAN) published 
in 2010 specified target protein intake based on 
the infant’s weight category. ESPGHAN suggested 
a goal of 3.0-4.5g protein/kg/day for infants up to 
one kilogram and 3.5 to 4.0 gram protein/kg/day 
for infants weighing 1000gram to 1800grams.37 
These recommendations suggest that some small-
er infants have higher protein needs, which may 
not be met by fixed protein concentrations in 
standard multi-nutrient fortifiers. 
 NICUs have adopted the practice of 
providing additional fortifier to increase the calor-
ic content of EBM for infants <2kg not meeting the 
goal weight gain rate of 15-20g/kg/d.34 In this 
way, calorie and protein concentration provided 
in the NICU is based on the infant’s weight and 
weight gain rate. The hypothesis is that more indi-
vidualized administration of protein and calories 
will prevent growth deficits. However, this strate-
gy is not time sensitive because weight and height 
growth trends have to be established and consid-
ered within the context of the typical weight loss 
seen after birth. It may take up to two weeks or 
longer for premature infants to regain their birth 
weight, which is considered a normal physiologic 
process. If a baby is born small-for-gestational age, 
there is need for additional catch-up growth to 
reach the 50tth percentile weight for gestational 
age, which represents appropriate-for-gestational 
age (AGA) weight. In essence, weight gain trends 
must be established over several weeks thus pro-
longing the time frame to determine whether ad-
ditional fortification is required to support ade-
quate growth. Thus, on the one hand, the disad-
vantage of fortifying based on growth trends is 
that the additional protein fortification may be 
initiated after a protein deficit has started to ac-
crue making it more difficult to reach intrauterine 
P a g e  | 9 
 
 
growth rates. Although the ideal time frame to 
reach AGA has not been identified for clinical 
practice, growth studies often measure percentage 
of infants who reach AGA or achieve intrauterine 
growth rates by discharge. On the other hand, for-
tifying based on weight and growth trends may 
run the risk of exceeding the infant’s tolerable 
upper limit of osmolality or micronutrient needs 
thus potentially increasing the risk of adverse clin-
ical outcomes. 
 
What indicators should be used to determine 
individualized fortification? 
 The use of biomarkers as an indicator of 
protein status seems like a more specific means of 
determining adequacy of protein intake. 
Arslanoglu et al. (2013) 49 individualized addition-
al protein supplementation according to twice 
weekly measurements of blood urea nitrogen 
(BUN), a biomarker expected to indicate inade-
quate or excessive protein intake. If BUN was 
<9mg/dl additional protein was provided to the 
multi-nutrient HMF. This study enrolled infants 
with a wide range of birth weights (600-1750g) 
and gestational age (26-34weeks). This strategy is 
potentially advantageous because it measures 
adequacy of intake and tolerance for the individu-
al infant and is time sensitive without waiting to 
see a trend of weight gain related to intake. 
 This study found that protein modular 
supplementation according to BUN levels in addi-
tion to a standard multi-nutrient fortifier resulted 
in greater protein intake, greater weight gain 
(17.5 + 3.0 v 14.4 + 3.0g/kg/d), and greater in-
creases in head circumference (1.4 + 0.3 v 1.0 + 
0.3cm/wk) compared to those receiving breast 
milk supplemented with a standard multi-nutrient 
fortifier.  Arslanoglu et al. (2013) reported: “In-
fants receiving the adjusted regimen had mean 
protein intakes of 2.9, 3.2, and 3.4g/kg/d, respec-
tively, in weeks 1, 2, and 3, whereas infants receiv-
ing the standard regimen had intakes of 2.9, 2.9, 
2.8g/kg/d, respectively.”49 This greater protein 
intake in the adjusted regimen group, including 
3.2 and 3.4g/kg/d, did not result in BUN levels 
>20mg/dl, the upper limits of normality. These 
results refute prior claims from studies in the 
1980s that protein intake of 3 g/kg/d at two 
weeks of age should be the upper limit of intake in 
order to prevent exceedingly high BUN levels.20 
Even though it has been shown previously that 
fluctuations in BUN levels may occur in preterm 
infants regardless of the adequacy of their protein 
intake due to immaturity of the infant’s renal sys-
tem35, this study supports the use of using BUN as 
a biomarker for safety of additional protein fortifi-
cation because none of the infants in the study 
developed necrotizing enterocolitis, sepsis, hyper-
aminoacidemia, or BUN levels above the normal 
limits while also achieving better growth out-
comes. 
 Rather than determining fortification 
based on metabolic effects, one strategy is to en-
sure the breast milk available from either mothers 
or donors is fortified to meet the nutrition rec-
ommendations. Using approximated or assumed 
levels of protein based on expected average com-
position of premature expressed breast milk plus 
fortifiers of known protein content (termed “blind 
fortification”) risks inadequate49 as well as exces-
sive protein intake. Miller et al. (2012) measured 
the content of the EBM with infrared spectroscopy 
after fortifying the breast milk in order to obtain a 
more accurate estimation of protein provision and 
macronutrient distribution. Other studies have 
validated such a technique to be used in order to 
individualize fortification according to the content 
of breast milk thus reducing variability in nutrient 
intake to reach the nutrition recommenda-
tions.38,39 However, the use of additional equip-
ment requiring well-trained staff in order to indi-
vidualize macronutrient composition of feeds dai-
ly is neither practical nor financially feasible in 
most NICU settings. Both Miller et al. (2012) and 
Arslanoglu et al. (2013) used nutrient modular 
supplements to fortify with additional protein, 
which increases room for error and potential for 
contamination. Again, the variability of breast 
milk composition within both a single day and 
over weeks make it difficult to know exactly how 
much protein the infant receives at each feed if 
measurements are conducted only periodically. 
 A practical way to analyze the macronu-
trient and micronutrient content of fortified 
breast milk has yet to be identified. At this time, 
there lacks evidence of a strategy as to how best to 
individualize nutrient intake. While there is evi-
dence to support increased protein content of the 
commercial human milk fortifiers, using fixed for-
tification according to manufacturer’s guidelines 
appears adequate to support greater short-term 
growth among some preterm infants and not in 
others. Studies individualizing protein fortification 
are heterogenous in design (number of days re-
ceiving HMF, initiation of enteral nutrition, vol-
ume rate of continuous enteral feeds, criteria for 
enteral volume advancement(increase), accompa-
nying TPN administration, goal volumes) and are 
thus difficult to interpret.  
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 Given all of these variations in nutrition 
protocols, simply adhering to a defined protocol 
for standard fortification and enteral nutrition 
administration in itself can improve health out-
comes.1,18,7,11, A 2009 nurses survey of Level II & 
III NICUs found that while 60.9% had an enteral 
nutrition protocol for the preterm infant, only 
26.6% actually adhered to their protocol in daily 
practice indicating there was variation in nutrition 
care.1 Creating an evidence-based protocol with an 
algorithm to manage growth failure or feeding 
intolerance could reduce variability in decision-
making as to whether additional fortification or 
other changes in the nutrition plan of care are 
necessary to optimize growth outcomes and min-
imize adverse clinical outcomes.  
 
Are powder HMF safe to use for premature in-
fants? 
 The majority of studies on multi-nutrient 
human milk fortifiers have used commercial pow-
dered products rather than liquid formulations, 
which may undermine conclusions about the ade-
quacy of nutrient content for optimal outcomes. 
Powdered fortifiers, such as Enfamil Human Milk 
Fortifier and Nestle FM 85, are well tolerated in 
preterm infants but have not necessarily facilitat-
ed better short-term growth rates compared to 
pre-term formulas.24,50 Cases of E.sakazakii infec-
tions leading to meningitis, bacteremia, and NEC 
in preterm infants fed powdered infant formulas 
prompted the CDC and FDA to release statements 
in 2001 and 2002, respectively, discouraging the 
use of powdered human milk fortifiers for pre-
term infants because they are not sterile.51,52 An 
in-vitro study on the growth of E.sakazakii in 
breast milk and breast milk fortified with pow-
dered Enfamil HMF compared to powdered infant 
formulas concluded that “powdered infant formu-
la yielded higher population densities [of E. sa-
kazakii] than those in breast milk or breast milk 
with fortifiers at all temperatures [10, 23, 37oC]”.53 
This is worrisome considering parents of preterm 
often receive recommendations to fortify EBM 
with powdered infant formulas upon discharge 
from the NICU. Another study by Chan et al. 
(2003) found that while preterm human milk has 
anti-microbial properties against E.coli, Staph, 
E.sakazakii, Group B Strep, adding Enfamil HMF 
powder to breast milk removed the antibacterial 
action compared to Similac HMF powder or MCT 
oil.54 However, a more recent study by Santiago et 
al. (2005) failed to show any differences between 
the two powdered fortifiers on bacterial growth in 
human milk.33 Regardless of the conflicting exper-
imental data on the anti-microbial properties of 
powder HMF, the E.sakazakii-related incidences of 
NEC have phased out the use of powdered HMF in 
most NICUs in favor more sterile options.  
 
Liquid HMF concerns: Does the risk of metabolic 
acidosis (with use of acidified liquid HMF) war-
rant preferential use of non-acidified, lower 
protein liquid HMF? 
 Older generation liquid HMF were not 
concentrated so their addition to breast milk di-
luted the bioactive components and nutrient con-
tent. New liquid fortifiers are highly concentrated 
to minimize this dilution. An updated liquid forti-
fier Enfamil Acidified Liquid HMF (Mead Johnson) 
was introduced in the US in 2012 followed by Sim-
ilac concentrate liquid HMF (Abbott Nutrition) in 
early 2013. Enfamil Acidified Liquid HMF (LHMF) 
and Similac LHMF increases caloric content of 
EBM from 20kcal/oz to an estimated 24kcal/oz. In 
addition, a human-milk protein based fortifier 
named Prolacta was developed in 2010. Prolacta 
is a fortifier derived from concentrated donor 
human milk. See Table 5 for a comparison of 
popular US human milk fortifiers. All of these liq-
uid fortifiers are considered sterile but have pre-
sented drawbacks of their own. 
 The liquid formulation of Enfamil HMF 
uses the naturally acidic whey protein isolate hy-
drolysate, which results in an acidic pH of ~4.3-
4.7.55  While this pH is similar to the gastric pH of 
a premature infant there are concerns that the 
Enfamil LHMF increases risk of metabolic acidosis, 
NEC, feeding intolerance, reflux, and loose stools. 
Gastric acidity becomes a concern when gastric pH 
drops below 4, an occurrence seen in infants with 
gastroesophageal reflux disease. 56  Nonetheless, 
metabolic acidosis can lead to impaired growth 
and decreased bone mineral density due to the 
excessive chronic acid interfering with calcium 
absorption. Metabolic acidosis occurs more fre-
quently in premature infants because of the lim-
ited capacity of their immature kidneys and great-
er endogenous acid production. A recent trial 
among 150 preterm-LBW infants57 comparing the 
use of Enfamil powdered HMF to Enfamil liquid 
HMF showed significantly higher HCO3 on two 
days of the twenty-eight day study. However, only 
one of those infants was diagnosed as having aci-
dosis and it did not require clinical intervention. 
 Metabolic acidosis from intake of Enfamil 
LHMF could be attribute to the pH or due to the 
higher protein content. The trial using the Enfamil 
liquid HMF, which has a higher protein content 
than the powdered formulation, showed that feed-
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ing tolerance was not an issue among preterm-
LBW infants. In terms of growth outcomes, weight 
gain rate with use of Liquid human milk fortifier 
was similar to powder HMF but length growth 
rate was greater in those infants receiving the liq-
uid human milk fortifier. By study day 28, infants 
receiving >80% of energy intake from breast milk 
fortified with liquid HMF achieved absolute great-
er weight and length than the powder HMF. 
 No study is yet available comparing 
growth and health outcomes associated with the 
use of an acidified liquid HMF, such as Enfamil 
LHMF, versus a liquid HMF with a more neutral 
pH but lower protein content, such as Similac 
LHMF. The results of a trial comparing Similac 
LHMF and Enfamil LHMF would be interesting to 
see also given the difference in nutrient content 
between these two LHMF. Such a study would edi-
fy clinical practice by determining whether the 
benefit of higher protein content of Enfamil on 
growth outcomes outweighs the risk of metabolic 
acidosis and feeding intolerance due the product’s 
acidic pH profile. Enfamil LHMF provides enough 
protein in order to reach the minimal protein to 
energy ratio of 3g protein:100kcal34 for LBW in-
fants and a protein intake between 3.3 and 
3.8g/kg/d.40 This protein level in Enfamil LHMF 
contains ~20% more protein than the Enfamil 
powder HMF (Mead Johnson),55 Similac Powder 
HMF (Abbott), and the Similac Liquid HMF (Ab-
bott). Similac LHMF provides approximately 15-
20% less protein, significantly lower levels of iron 
and vitamin D, and significantly higher levels of 
other minerals and trace elements compared to 
Enfamil LHMF.58 The protein content in Similac 
LHMF is not adequate and requires additional pro-
tein modular supplement to meet protein needs of 
the premature infant. The infant receiving Similac 
LHMF, as opposed to Enfamil LHMF, would also 
require an additional iron supplement to meet the 
minimum intake of 2 mg iron/kg.13 As mentioned 
earlier, use of modular supplements does increase 
risk of infection and NEC due to potential contam-
ination during preparation. However, Similac 
LHMF may have the advantage of promoting ade-
quate bone mineralization to prevent osteopenia 
and fractures given the much higher levels of cal-
cium, phosphorus, magnesium, and zinc. On the 
contrary these very high levels of calcium could 
impair fat absorption and lead to feeding intoler-
ance as cautioned earlier. Enfamil LHMF provides 
the advantage of higher nutrient content thus re-
ducing the need for supplements. Currently the 
debate is whether to use the acidified liquid forti-
fiers, such as Enfamil LHMF, risking metabolic 
acidosis and feeding intolerance or use Similac 
plus a modular iron and protein supplement to 
meet protein needs, which may yet risk infection 
and NEC.  
 
Does a human milk-based fortifier confer ad-
vantages over bovine milk-based fortifiers? 
 Similac LHMF is not the only alternative 
to Enfamil LHMF. The introduction of a human 
milk protein-based HMF offers the potential of 
reducing the issues with metabolic acidosis, feed-
ing intolerance and NEC. Prolacta HMF is a liquid 
human milk protein-based fortifier that when 
provided with an exclusive breastmilk diet has 
been shown to reduce odds of NEC by 77% com-
pared to bovine milk protein-based fortifiers.59 
Yet in this randomized clinical trial the rate of 
weight gain was greater among the premature-
LBW infants that received bovine protein-based 
HMF compared to the human milk protein-based 
fortifier (16.0 + 7.8 vs 14.3 + 3.8g/kg/d, P= .051). 
This rate of weight gain with Prolacta HMF is close 
to meeting the minimum goal of 15g/kg/d. Addi-
tional analyses reported a 11-14% reduction in 
likelihood of re-initiating TPN after full enteral 
feeds were achieved of breastmilk fortified with 
human milk-proteins compared to human milk 
supplemented with bovine milk-based fortifier or 
pre-term formula.60 It is assumed that feeding in-
tolerance and/or metabolics acidosis issues would 
be improved using a human milk-based fortifier 
due to the similar whey &casein protein content 
as breast milk. However, further studies are need-
ed to evaluate these outcomes in addition to the 
effects on bone mineral density in premature in-
fants. 
 Despite these advantages, the cost of Pro-
lacta HMF may be beyond the financial capabilities 
of many hospitals. The cost of the Prolacta HMF, 
estimated to be $6.25 per ml, is far more expen-
sive compared to the $1.30 per packet of Enfamil 
or Similac powder HMF.61A cost-saving effective-
ness analysis showed that the cost of NEC man-
agement and treatment and costs of hospitaliza-
tion were greater than the cost of Prolacta as HMF 
and use of donor milk to provide an exclusively 
human milk based diet to premature-LBW infants. 
The use of an exclusively human-milk based diet 
reducing probability of NEC and surgical NEC, 
length of stay, and use of medical intervention 
resulting in an estimated net direct savings of 
$8,167 per extremely premature infant.61 These 
cost-savings in the long term may be appealing if 
standard fortification of breast milk with human 
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milk-based fortifier can consistently deliver im-
proved health outcomes. 
 
Conclusion & Summary 
 Following current scientific evidence, it 
has become standard practice to in the NICU to 
fortify breastmilk for premature-LBW infants. The 
aim is to provide immune benefits of breast milk 
and increase nutrient content of premature and 
mature donor milk when needed to support 
growth, bone mineralization, gastrointestional 
function, and immune modulation. Evidence sup-
ports that while breast milk fortification can de-
crease morbidity and mortality in these at-risk 
infants, higher protein content is needed in the 
human milk fortifiers in order to achieve short-
term intrauterine growth rates for the sake of 
long-term health benefits, such as neurocognitive 
development. In addition, criteria for evaluating 
optimal growth and development primarily in 
terms of weight gain rate may need to be revised 
to take into account long-term growth. Other an-
thropometric measures, such as weekly increase 
in head circumference, have shown to be better 
predictors of long-term outcomes, such as neu-
rocognitive development, than achieving intra-
uterine weight gain. Identifying ideal growth pa-
rameters that are related to longer-term out-
comes, such bone mineralization, growth, chronic 
diseases, and allergies in later childhood and 
adulthood, can help establish more appropriate 
criteria for human milk fortification strategies in 
preterm-LBW infants. 
 Current evidence suggests fortifying with 
personalized criteria, such as plasma urea, to pro-
vide optimal protein and micronutrients without 
increasing risk of NEC, feeding intolerance, meta-
bolic acidosis, or hyperaminoacidemia. Individual-
izing protein intake seems like the way forward in 
order to manage the many health complications 
and unique nutrient needs for premature infants. 
This approach may be beneficial in promoting 
growth but, again, effective strategies based on 
growth outcomes or biomarkers need to be de-
fined. Research is needed to determine the best 
fortification strategies when using donor milk ver-
sus preterm mother’s own milk to ensure ade-
quate intake. Similarly, fortification algorithms 
should be delineated to help manage feeding in-
tolerance issues and other common medical issues 
in preterm infants. In the meantime, BUN levels 
can be used as a guidance to ensure protein is not 
provided in excess protein.   
 With the recent advent of liquid human 
milk fortifiers, issues with sterility and inappro-
priate osmolality of commercial multi-nutrient 
fortifiers have been minimized. However, further 
research is needed to assess the efficacy of higher 
protein fortifiers and whether the protein levels in 
the fortifiers can reach the current recommenda-
tions without additional modular supplements. In 
addition, there is no evidence that acidified liquid 
HMF is associated with clinically significant det-
rimental health outcomes but limiting the protein 
content of liquid HMF should be avoided. 
 Human milk fortification is just one as-
pect of nutrition care for premature infants and 
must be integrated into best practices including 
aggressive parenteral nutrition, early trophic en-
teral feeding, breastfeeding and lactation support 
for mothers, and clinical algorithms for common 
medical issues among premature-LBW infants. 
NICU practice guidelines need to be updated to 
meet evidence-based recommendations for enter-
al nutrition regimens in order to reduce extra-
uterine growth restriction among premature-LBW 
infants. 
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Table 5: Nutrient Composition of Preterm Human Milk and Human Milk Fortifiers 
 
*limited nutrient information available
 Energy Carbohy-
drate   
(g/dL) 
Protein 
(g/dL) 
Fat 
(g/dL) 
Calci-
um 
(mg/dL) 
Phos-
phorus 
(mg/dL) 
Magne-
sium 
(mg/dL) 
Potassi-
um 
(mg/dL) 
Sodi-
um 
(mg/dL) 
Zinc 
(mg/dL) 
Iron 
(mg/dL) 
Vita-
min D 
(IU/dL) 
Human 
milk pre-
term34 
68kcal/ml 10  1.4 5.8 28  14  * * * * * * 
Enfamil 
Powder 
HMF55 
14kcal/4 
packets add 
100ml BM 
<0.4 1.1 1.05L 90  50  1  29 16 0.72  1.44 150  
Similac 
Powder 
HMF58 
14kcal/4 
packets 
1.8 1.0 0.36 117 67 7.0 63 15 1.0  0.35 120 IU 
Enfamil 
Liquid 
HMF55 
30kcal/4 
vials 
<1.2 2.2 2.3 116 63 1.84 45  0.96 1.76 188 
Similac  
Liquid 
HMF58 
27.4/ 
4 packets 
3.2 1.4 1.06 140 80 8.64 83 22 1.22 0.428 140 
Prolact 
+4HMF62 
82kcal/dL 
(10ml HMF/ 
40ml BM) 
0.9g/10mL 0.6g/10
ml 
0.9g/1
0ml 
51.5mg
/10mL 
36mg * * * 0.3mg/
10ml 
* 13 
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